WO2012002640A2 - 도네페질을 함유하는 경피흡수제제 - Google Patents
도네페질을 함유하는 경피흡수제제 Download PDFInfo
- Publication number
- WO2012002640A2 WO2012002640A2 PCT/KR2011/003052 KR2011003052W WO2012002640A2 WO 2012002640 A2 WO2012002640 A2 WO 2012002640A2 KR 2011003052 W KR2011003052 W KR 2011003052W WO 2012002640 A2 WO2012002640 A2 WO 2012002640A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- transdermal
- donepezil
- matrix layer
- agent
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
Definitions
- the present invention relates to a transdermal absorption agent including donepezil or a salt thereof as an active ingredient, and more particularly, to a transdermal absorption agent including a drug-containing matrix layer formed of a matrix with an acrylate-rubber hybrid adhesive. It is about.
- Dementia is a syndrome characterized by complex cognitive impairments, including memory loss, loss of intelligence, personality changes, and behavioral problems.
- This symptom is a degenerative brain neuropathy related to the brain, the central nervous system, resulting in irreversible dysfunction of the neural network by the death of slow neurons that cause central nervous system degenerative disease, and eventually permanent loss of the human body. Will result.
- a common feature of degenerative neuropathy is the overall or specific cell death. Differentiated neurons are incapable of regenerative, resulting in the loss of irreversible brain function.
- Cholinesterases come in two forms: acetylcholinesterase (AChE) and butylcholinesterase (BuChE).
- the acetylcholinesterase is an enzyme that hydrolyzes acetylcholine, one of the neurotransmitters that mediate the activity of parasympathetic nerves in the body, to choline and acetate, and is formed on the endoplasmic reticulum membrane and moves to the cell membrane to perform its function. .
- the enzyme is most widely distributed in the choline nerve and its surroundings, especially in the muscle nerve junction, and is an important enzyme found in plasma, liver and other tissues.
- Alzheimer's treatment for dementia is mainly an acetylcholinesterase inhibitor, an acetylcholine degrading enzyme, and is donepezil (Donepezil, trade name: Aricept), rivastigmin (trade name: Exelon), galantamine (Galantamine). , Brand name: reminyl), and the like.
- donepezil was licensed for dementia patients from the US Food and Drug Administration (FDA) in 1996, and is used to treat dementia of mild and moderate dementia of Alzheimer's disease.
- Donepezil is a drug having the effect of reversibly inhibiting acetylcholine degrading enzymes called acetylcholinesterase and butylcholinesterase, and acetylcholine, a neurotransmitter, is lowered than the normal person through the above inhibitory function.
- acetylcholinesterase and butylcholinesterase acetylcholine degrading enzymes
- acetylcholine a neurotransmitter
- the donepezil preparations currently in use are in tablet form and are prescribed to Alzheimer's dementia patients via oral administration.
- the donepezil oral preparations are unable to avoid the first pass of the liver, and as a result, it is easy to affect the liver function, and because of the high concentration in the digestive tract, side effects have been reported.
- Japanese Patent Laid-Open Publication No. 1999-315016 proposes ointments and suppositories for rectal administration.
- these formulations may not be suitable for continuous administration of the active ingredient over a long period of time in a single dose.
- US Patent Publication No. 2004/0258741 and Korean Patent Publication No. 10-2005-0037405 disclose styrene-isoprene-styrene (SIS) and / or polyisobutylene (PIB) series.
- SIS styrene-isoprene-styrene
- PIB polyisobutylene
- a transdermal absorption agent using a synthetic rubber polymer has been disclosed.
- the area was manufactured more than necessary to overcome this problem, so when the transdermal absorption preparation is applied to the patient for 1 to 2 days at a time, the patient's compliance may be reduced.
- the transdermal absorption agent is difficult to contain a high concentration of the drug because when the concentration of the drug in the matrix is more than 8%, solid crystals are formed, which may cause a decrease in adhesion, non-uniformity of skin penetration rate and storage problems. There is a point.
- US Patent Publication Nos. 2010/0080842, 2008/0138388, and 2009/0175929 use acrylic pressure-sensitive adhesives having a carboxylic acid function or a hydroxyl function, and use a specific permeation accelerator or a specific crystal form of donepezil ( A transdermal absorption agent using Form-B crystals) or a specific anti-crystallization agent ((meth) acrylate copolymer having a carboxyl group) has been disclosed.
- Korean Patent Laid-Open Publication No. 10-2009-0101667 discloses a transdermal absorption preparation using an EVA (ethylene vinyl acetate) adhesive and a rosin ester resin as an anti-crystallization agent.
- the present invention provides a transdermal absorption agent including donepezil or a salt thereof as an active ingredient, and exhibits a high skin permeability and can continuously maintain a therapeutically effective blood concentration for at least 24 hours.
- the present invention provides a transdermal absorption preparation capable of preventing recrystallization of donepezil and maintaining skin permeability even during long-term storage.
- the present invention provides a donepezil-containing transdermal absorption preparation that exhibits high skin permeability continuously for 24 hours or more and has excellent stability.
- a drug-containing matrix layer comprising (a) donepezil or a pharmaceutically acceptable salt thereof as an active ingredient and (b) an acrylate-rubber hybrid as an adhesive.
- a transdermal absorption preparation is provided.
- the transdermal absorption agent may be composed of a support layer, a drug-containing matrix layer, and a release layer.
- the acrylic-rubber hybrid adhesive may include an acrylic polymer including a C 4 to C 18 alkyl acrylate monomer grafted with a rubber macromer having a glass transition temperature of about ⁇ 30 ° C. or less.
- the acrylic-rubber hybrid pressure-sensitive adhesive may be contained in the range of 60 to 90% by weight based on the total weight of the drug-containing matrix layer.
- the donepezil or a pharmaceutically acceptable salt thereof may be contained in the range of 5 to 40% by weight based on the total weight of the drug-containing matrix layer.
- the transdermal absorption agent according to the present invention may further include an acrylate-based or methacrylate-based polymer as an anti-crystallization agent, and the content of the anti-crystallization agent is in the range of 1 to 10% by weight based on the total weight of the drug-containing matrix layer.
- the anti-crystallization agent may be a 1: 2: 1 (weight ratio) copolymer of butyl methacrylate, (2-dimethyl aminoethyl) methacrylate, and methyl methacrylate.
- the transdermal absorption preparation terpenes (Terpenes); Surfactants; Polyoxyethylene alkyl ethers; Fatty alcohols; Sugar esters; Glycerols; Alkyl 2-ethyl hexanates; And a dietary accelerator selected from the group consisting of diethoxylethyl succinates, wherein the content of the promoter is 1 to 20% by weight based on the total weight of the drug-containing matrix layer. It can be a range.
- the permeation accelerator may be preferably at least one selected from the group consisting of polyethylene glycol palm kernel glyceride, polyoxyethylene lauryl ether, polyglyceryl-3 oleate, lauryl alcohol, and oleyl alcohol.
- the transdermal absorption agent according to the present invention can increase the diffusion rate of donepezil from the matrix layer by forming a matrix using an acrylate-rubber hybrid as an adhesive. Accordingly, the transdermal absorption preparations according to the present invention not only exhibit high skin permeability but also maintain a therapeutically effective blood concentration for at least 24 hours continuously. In addition, recrystallization of donepezil can be prevented even during long-term storage, and skin permeability can be maintained as it is. Therefore, the transdermal absorption preparations according to the present invention can greatly improve the compliance of patients with Alzheimer's disease.
- 1 is a result of measuring the skin permeability of the percutaneous absorption preparation according to the type of adhesive.
- Figure 2 is the result of measuring the skin permeability of the percutaneous absorption agent according to the permeation accelerator.
- Figure 3 compares the skin permeability of the transdermal absorption preparation including the donepezil of the present invention and the transdermal absorption preparation using the prior art (US Patent Publication No. 2008/0138388).
- Figure 4 compares the skin permeability of transdermal absorbents using the prior art transdermal absorbents including the donepezil of the present invention (US Patent Publication No. 2009/0175929).
- the "acrylate-rubber hybrid" adhesive refers to a polymer in which a rubber macromer is grafted to an acrylic polymer, for example, US Pat. Polymers disclosed in 6,670,417, and the like.
- the acrylic-rubber hybrid adhesive is an acrylic polymer comprising a C 4 to C 18 alkyl acrylate monomer grafted with a rubber macromer having a glass transition temperature of -30 ° C. or less. polymer) and more preferably a commercially available acrylic-rubber hybrid, ie Duro-Tak TM 87-502A, Duro-Tak TM 87-503A, and Duro-Tak TM 87-504A (National Starch).
- One or more adhesives selected from the group can be used.
- the present invention provides a transdermal absorbent preparation comprising (a) a donepezil or a pharmaceutically acceptable salt thereof as an active ingredient and (b) an acrylate-rubber hybrid as an adhesive. to provide.
- the transdermal absorption agent may be composed of a support layer, a drug-containing matrix layer, and a release layer.
- the transdermal absorbent according to the present invention uses an acrylic-rubber hybrid as an adhesive, and the acrylic-rubber hybrid adhesive forms a matrix of the drug-containing matrix layer. That is, the drug-containing matrix layer is formed by evenly dispersing donepezil or a pharmaceutically acceptable salt thereof in the acrylic-rubber hybrid adhesive.
- the acrylic-rubber hybrid adhesive has a low glass transition temperature, and the matrix formed therefrom can improve the fluidity of the polymer chains, so that the active ingredient (i.e., donepezil or its pharmaceuticals from the matrix layer toward the skin) can be improved. It has been found by the present invention that the rate of diffusion of salts, which is generally acceptable, can be increased.
- hydroxy or carboxylic acid functional groups as well as acrylic pressure sensitive adhesives (eg, Duro-Tak TM 87-4098, Duro-Tak TM 87-900A, Duro-Tak TM 87-9301, etc.) that do not contain functional groups.
- acrylate pressure-sensitive adhesive having a (e.g., Duro-Tak TM 87-2516, Duro -Tak TM 87-2510, Duro-Tak TM 87-2525, Duro-Tak TM 87-2596, Duro-Tak TM 87- 2825, Duro-Tak TM 87-2502, Duro-Tak TM 87-2979, Duro-Tak TM 87-2074, etc.), when the acrylic-rubber hybrid adhesive is used, it can exhibit high skin permeability and excellent adhesion. Indicates.
- the acrylic-rubber hybrid pressure-sensitive adhesive may be used in an amount sufficient to form a matrix layer, for example, may be contained in the range of 60 to 90% by weight relative to the total weight of the drug-containing matrix layer.
- the donepezil or a pharmaceutically acceptable salt thereof may be used in an amount sufficient to obtain a therapeutically effective blood concentration, for example, a drug-containing matrix layer. It may be contained in the range of 5 to 40% by weight, preferably 10 to 20% by weight based on the total weight. If the content of donepezil or a pharmaceutically acceptable salt thereof exceeds 40% by weight, crystals of the drug may be formed in the transdermal absorbent, resulting in a decrease in adhesion or a decrease in the absorption rate of the drug.
- Transdermal absorption preparations according to the invention may further comprise an anti-crystallization agent.
- an anti-crystallization agent an acrylate-based or methacrylate-based polymer may be used, and preferably 1: 2: 1 (butyl methacrylate, (2-dimethyl aminoethyl) methacrylate, and methyl methacrylate). Weight ratio) copolymers (eg Eudragit E100, etc.) may be used.
- the content of the anti-crystallization agent may be in the range of 1 to 10% by weight based on the total weight of the drug-containing matrix layer.
- the percutaneous absorption preparation according to the present invention may include a permeation accelerator commonly used in the field of percutaneous absorption, the content of the permeation accelerator is 1 to 20% by weight, preferably based on the total weight of the drug-containing matrix layer May range from 5 to 15% by weight.
- the content of the permeation accelerator is more than 20% by weight, cold flow may occur due to a decrease in the adhesion of the transdermal absorbent to the skin or a weakening of the cohesion.
- the permeation promoters are terpenes; Surfactants; Polyoxyethylene alkyl ethers; Fatty alcohols; Sugar esters; Glycerol; Alkyl 2-ethyl hexanates; It may be selected one or more from diethoxylethyl succinate and the like.
- terpenes examples include cineole, limonene, and the like.
- surfactant examples include isopropyl myristate, isopropyl palmitate, 2- (2-ethoxyethoxy) ethanol, oleic acid oleyl ester (oleic acid oleyl ester), caprylocaproyl macrogolglyceride, oleoyl macrogolglyceride, diisopropyl dirrerate, diisopropyl adipate , Hexyl laurate, polysorbate, sorbitan oleate and the like.
- polyoxyethylene alkyl ethers examples include polyethylene glycol palm kernel glyceride, 2-ethyl hexyl hydroxystearate, polyoxyethylene lauryl ether ), Polyoxyethylene cetyl ether, and the like.
- fatty alcohols examples include polyglyceryl-3 oleate, polyethylene glycol almond glyceride, lauryl alcohol, oleyl alcohol, and the like. do.
- sugar esters examples include sucrose stearate, sucrose palmitate, sucrose laurate, sucrose behenate, sucrose oleate ), Sucrose erucate and the like.
- alkyl 2-ethylhexanonates examples include 2-ethylhexanonate, cetyl 2-ethylhexanonate, and stearyl 2-ethylhexanoate. ethylhexanonate) and the like.
- polyoxyethylene alkyl ethers and / or fatty alcohols can be preferably used. More preferably, the permeation accelerator is polyethylene glycol palm kernel glyceride (eg Crovol TM A40), polyoxyethylene lauryl ether (eg Brij TM 30, Brij TM 52, etc.), polyglyceryl-3 One or more selected from the group consisting of oleate (eg, Plurol oleique TM cc497), lauryl alcohol, and oleyl alcohol. Especially preferably, polyoxyethylene lauryl ether (eg Brij TM 30) can be used as permeation accelerator.
- polyethylene glycol palm kernel glyceride eg Crovol TM A40
- polyoxyethylene lauryl ether eg Brij TM 30, Brij TM 52, etc.
- polyglyceryl-3 One or more selected from the group consisting of oleate (eg, Plurol oleique TM cc497), lauryl alcohol
- the transdermal absorbent preparation of the present invention can be prepared by forming the above-described drug-containing matrix layer on the release layer and again forming a support layer thereon.
- the release layer may be a release liner or a laminate thereof commonly used in the field of transdermal absorbents, for example, polyethylene, polyester, polyvinyl chloride, polyvinylidene coated with silicone resin or fluorine resin. Films such as chloride, paper or laminates thereof can be used.
- the support layer (also referred to as a backing membrane) can also be used a drug-non-absorbing and flexible material commonly used in the field of transdermal absorbents, for example, polyolefin, polyether ( polyether, multi-layer ethylene vinyl acetate film, polyester, polyurethane, and the like may be used.
- a drug-non-absorbing and flexible material commonly used in the field of transdermal absorbents, for example, polyolefin, polyether ( polyether, multi-layer ethylene vinyl acetate film, polyester, polyurethane, and the like may be used.
- the transdermal absorption agent of the present invention dissolves donepezil or a pharmaceutically acceptable salt thereof and an acrylic-rubber hybrid adhesive in an appropriate solvent (eg, ethyl acetate, etc.), and optionally the permeation accelerator and And / or a solution obtained by dissolving the anti-crystallization agent together, for example, may be prepared by applying a drying sheet coated with silicone to dry, and then laminating a supporting layer.
- an appropriate solvent eg, ethyl acetate, etc.
- the permeation accelerator and And / or a solution obtained by dissolving the anti-crystallization agent together for example, may be prepared by applying a drying sheet coated with silicone to dry, and then laminating a supporting layer.
- the percutaneous absorption preparation was prepared according to the ingredients and contents of Table 1 below. That is, ethyl acetate used as a solvent in the donepezil and acrylic-rubber hybrid adhesives, optionally, the permeation accelerator and / or the anti-crystallization agent (Euragit E100), was added to a solid content of 25% and dissolved with stirring. . The obtained solution was applied to a release liner coated with silicon, dried, and then laminated with polyethylene film to form a backing membrane to prepare a transdermal absorbent containing donepezil.
- Table 1 The percutaneous absorption preparation was prepared according to the ingredients and contents of Table 1 below. That is, ethyl acetate used as a solvent in the donepezil and acrylic-rubber hybrid adhesives, optionally, the permeation accelerator and / or the anti-crystallization agent (Euragit E100), was added to a solid content of 25% and dissolved with stirring. . The obtained solution was applied to a release liner coated with silicon,
- the percutaneous absorption preparations were prepared according to the ingredients and contents of Table 2 below. That is, ethyl acetate used as a solvent in the donepezil and acrylic-rubber hybrid adhesives, optionally, the permeation accelerator and / or the anti-crystallization agent (Euragit E100), was added to a solid content of 25% and dissolved with stirring. . The obtained solution was applied to a release liner coated with silicon, dried, and then laminated with polyethylene film to form a backing membrane to prepare a transdermal absorbent containing donepezil. However, Comparative Example 6 used a release paper coated with a fluorine polymer (Scotchpak TM 1022) as the release paper.
- Scotchpak TM 1022 fluorine polymer
- Test Example 1 Measurement of Skin Permeability of Transdermal Absorption Composition According to Adhesive Type
- Skin permeability was measured by applying the transdermal absorption preparations prepared in Example 1 and Comparative Examples 1 to 6 to hairless mouse skin. Specifically, the skin of a hairless mouse (6 to 8 weeks old) was extracted immediately before the test, and each percutaneous absorbent was cut in a circle to have an area of 2 cm 2 and attached to the skin, followed by a flow-through diffusion device. The cells were clamped and the sample was put in isotonic phosphate buffer (pH 6.0) and kept at 37 ° C., and samples were taken for 24 hours at intervals of 4 hours with stirring with a magnetic stirrer. The obtained sample was quantified using high performance liquid chromatography under the analysis conditions shown in Table 3 below.
- the transdermal absorbent preparations according to the present invention exhibited high skin permeability compared to the transdermal absorbent preparations of Comparative Examples 7 and 8.
- the transdermal absorbent of Example 8 exhibited significantly higher skin permeability.
- the transdermal absorbent preparation according to the present invention exhibited high skin permeability compared to the transdermal absorbent preparation of Comparative Example 9.
- the transdermal absorbent of Example 10 showed a significantly higher skin permeability.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
구분 | 성분 | 실시예(중량%) | ||||||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ||
유효성분 | 도네페질 | 10 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 35 | 15 | 15 |
아크릴-고무하이브리드 점착제 | Duro-TakTM 87-502A | 90 | 85 | 80 | 80 | 80 | 80 | 80 | 75 | 55 | 74 | |
Duro-TakTM 87-503A | 37.5 | |||||||||||
Duro-TakTM 87-504A | 37.5 | |||||||||||
투과촉진제 | BrijTM 30 | 5 | 5 | 5 | 5 | 5 | ||||||
Plurol oleiqueTM CC497 | 5 | |||||||||||
CrovolTM A40 | 5 | |||||||||||
올레일 알콜 | 5 | |||||||||||
라우릴 알콜 | 5 | |||||||||||
BrijTM 52) | 5 | |||||||||||
결정화방지제 | 유드라짓TM E100(EudragitTM E100) | 5 | 5 | 6 |
구분 | 성분 | 비교예(중량%) | ||||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ||
유효성분 | 도네페질 | 10 | 10 | 10 | 10 | 10 | 10 | 15 | 35 | 30 |
점착제 | 폴리이소부틸렌계 점착제(Duro-TakTM 87-608A) | 90 | ||||||||
스티렌-부타디엔-스티렌계 점착제(KratonTM) | 90 | |||||||||
관능기 미포함 아크릴계 점착제(Duro-TakTM 87-4098) | 90 | |||||||||
히드록실기 포함 아크릴계 점착제(Duro-TakTM 87-2516) | 90 | 75 | 55 | 64 | ||||||
카르복실기 포함 아크릴계 점착제(Duro-TakTM 87-2677) | 90 | |||||||||
실리콘계 점착제(Dow Corning Bio-PSA 7-4302) | 90 | |||||||||
투과촉진제 | 라우릴 알콜 | 5 | 5 | |||||||
팔미트산 | 3 | |||||||||
올레인산 | 3 | |||||||||
결정화방지제 | 유드라짓TM E100(EudragitTM E100) | 5 | 5 |
분석칼럼 | C-18 (Gemini, 10 cm, 5 ㎛) |
이동상 | 아세토니트릴/인산염 완충액(pH 2.7) = 70/30 |
유속 | 1 ml/min |
분석파장 | 315 nm |
온도 | 30℃ |
Claims (11)
- (a) 유효성분으로서 도네페질 또는 그의 약학적으로 허용가능한 염 및 (b) 점착제로서 아크릴-고무 하이브리드(acrylate-rubber hybrid)를 포함하는 약물-함유 매트릭스층을 포함하는 경피흡수제제.
- 제1항에 있어서, 상기 경피흡수제제가 지지층, 약물-함유 매트릭스층, 및 박리층으로 구성된 것을 특징으로 하는 경피흡수제제.
- 제1항에 있어서, 상기 아크릴-고무 하이브리드 점착제가 -30 ℃ 이하의 유리전이온도를 갖는 고무 마크로머(rubber macromer)로 접합된(grafted) C4~C18 알킬 아크릴레이트 모노머를 포함하는 아크릴계 중합체(acrylic polymer)인 것을 특징으로 하는 경피흡수제제.
- 제1항에 있어서, 상기 도네페질 또는 그의 약학적으로 허용가능한 염의 함량이 약물-함유 매트릭스층 총 중량에 대하여 5∼40 중량%의 범위인 것을 특징으로 하는 경피흡수제제.
- 제1항에 있어서, 상기 아크릴-고무 하이브리드 점착제의 함량이 약물-함유 매트릭스층 총 중량에 대하여 60∼90 중량%의 범위인 것을 특징으로 하는 경피흡수제제.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 결정화 방지제로서 아크릴레이트계 혹은 메타크릴레이트계 중합체를 추가로 포함하는 것을 특징으로 하는 경피흡수제제.
- 제6항에 있어서, 상기 결정화 방지제의 함량이 약물-함유 매트릭스층 총 중량에 대하여 1∼10 중량%의 범위인 것을 특징으로 하는 경피흡수제제.
- 제6항에 있어서, 상기 결정화 방지제가 부틸 메타크릴레이트, (2-디메틸 아미노에틸) 메타크릴레이트, 및 메틸 메타크릴레이트의 1:2:1(중량비) 공중합체인 것을 특징으로 하는 경피흡수제제.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 터펜류(Terpenes); 계면활성제류(surfactants); 폴리옥시에틸렌 알킬 에테르류(polyoxyethylene alkyl ethers); 지방 알콜류(fatty alcohols); 당 에스테르류(sugar esters); 글리세롤류(glycerols); 알킬 2-에틸 헥사네이트류(alkyl 2-ethyl hexanates); 및 디에톡실에틸 석시네이트류(diethoxylethyl succinates)로 이루어진 군으로부터 1 종 이상 선택된 투과촉진제를 추가로 포함하는 것을 특징으로 하는 경피흡수제제.
- 제9항에 있어서, 상기 투과촉진제의 함량이 약물-함유 매트릭스층 총 중량에 대하여 1∼20 중량%의 범위인 것을 특징으로 하는 경피흡수제제.
- 제9항에 있어서, 상기 투과촉진제가 폴리에틸렌글리콜 팜 커넬 글리세라이드, 폴리옥시에틸렌 라우릴 에테르, 폴리글리세릴-3 올레이트, 라우릴 알콜, 및 올레일 알콜로 이루어진 군으로부터 1 종 이상 선택되는 것을 특징으로 하는 경피흡수제제.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11801047.9A EP2589379B1 (en) | 2010-06-30 | 2011-04-27 | Transdermal drug delivery system containing donepezil |
CN201180032581.1A CN103096882B (zh) | 2010-06-30 | 2011-04-27 | 含有多奈哌齐的经皮吸收制剂 |
AU2011272174A AU2011272174A1 (en) | 2010-06-30 | 2011-04-27 | Transdermal drug delivery system containing donepezil |
JP2013518221A JP5680197B2 (ja) | 2010-06-30 | 2011-04-27 | ドネペジルを含む経皮吸収製剤 |
ES11801047T ES2785992T3 (es) | 2010-06-30 | 2011-04-27 | Sistema de administración de fármacos transdérmico que contiene donepezil |
CA2804148A CA2804148C (en) | 2010-06-30 | 2011-04-27 | Transdermal drug delivery system containing donepezil |
SG2012093944A SG186777A1 (en) | 2010-06-30 | 2011-04-27 | Transdermal drug delivery system containing donepezil |
US13/806,565 US9155711B2 (en) | 2010-06-30 | 2011-04-27 | Transdermal drug delivery system containing donepezil |
US14/206,999 US20140370076A1 (en) | 2010-06-30 | 2014-03-12 | Transdermal drug delivery system containing donepezil |
US14/825,071 US9693970B2 (en) | 2010-06-30 | 2015-08-12 | Transdermal drug delivery system containing donepezil |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0062433 | 2010-06-30 | ||
KR20100062433A KR101192969B1 (ko) | 2010-06-30 | 2010-06-30 | 도네페질을 함유하는 경피흡수제제 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/806,565 A-371-Of-International US9155711B2 (en) | 2010-06-30 | 2011-04-27 | Transdermal drug delivery system containing donepezil |
US14/825,071 Continuation US9693970B2 (en) | 2010-06-30 | 2015-08-12 | Transdermal drug delivery system containing donepezil |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012002640A2 true WO2012002640A2 (ko) | 2012-01-05 |
WO2012002640A3 WO2012002640A3 (ko) | 2012-04-12 |
Family
ID=45402504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/003052 WO2012002640A2 (ko) | 2010-06-30 | 2011-04-27 | 도네페질을 함유하는 경피흡수제제 |
Country Status (12)
Country | Link |
---|---|
US (2) | US9155711B2 (ko) |
EP (1) | EP2589379B1 (ko) |
JP (1) | JP5680197B2 (ko) |
KR (1) | KR101192969B1 (ko) |
CN (1) | CN103096882B (ko) |
AU (1) | AU2011272174A1 (ko) |
CA (1) | CA2804148C (ko) |
ES (1) | ES2785992T3 (ko) |
MY (1) | MY163809A (ko) |
NZ (1) | NZ605352A (ko) |
SG (1) | SG186777A1 (ko) |
WO (1) | WO2012002640A2 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014502639A (ja) * | 2011-01-12 | 2014-02-03 | タイワン バイオテック カンパニー リミテッド | ドネペジル経皮吸収型パッチ及びアルツハイマー病の治療方法 |
US20140271866A1 (en) * | 2013-03-15 | 2014-09-18 | Nal Pharmaceuticals, Ltd. | Transdermal drug delivery system containing rivastigmine |
WO2014159778A1 (en) * | 2013-03-13 | 2014-10-02 | Nal Pharmaceuticals, Ltd. | Transdermal drug delivery system containing fentanyl |
WO2014159748A1 (en) * | 2013-03-13 | 2014-10-02 | Nal Pharmaceuticals, Ltd. | Transdermal drug delivery system containing donepezil |
US10195408B2 (en) | 2014-02-20 | 2019-02-05 | Nal Pharmaceutical Group Limited | Transdermal drug delivery system containing donepezil |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101317158B1 (ko) | 2011-02-18 | 2013-10-15 | 조선대학교산학협력단 | 갈란타민 또는 그의 염을 함유하는 경피흡수제제 |
KR101239150B1 (ko) * | 2012-02-28 | 2013-03-06 | 에스케이케미칼주식회사 | 도네페질-함유 경피흡수제제 및 그의 제조방법 |
AU2015363883B2 (en) * | 2014-12-18 | 2021-03-25 | Icure Pharmaceutical, Inc | Transdermal preparation containing donepezil as active ingredient |
EP3490541A2 (en) * | 2016-07-27 | 2019-06-05 | Corium International, Inc. | Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs byin situ |
WO2019079291A1 (en) | 2017-10-17 | 2019-04-25 | Lubrizol Advanced Materials, Inc. | COMPOSITION AND DEVICE FOR ADMINISTERING ACTIVE AGENTS ON SKIN SURFACES |
US20210251973A1 (en) * | 2018-08-31 | 2021-08-19 | Arctic Therapeutics, Llc | Novel topical formulation for intradermal application and uses thereof |
KR102372630B1 (ko) * | 2019-05-15 | 2022-03-14 | 주식회사 대웅제약 | 고함량의 도네페질 또는 그의 염을 포함하는 경피흡수제제 |
CN112823793A (zh) * | 2019-11-20 | 2021-05-21 | 成都康弘药业集团股份有限公司 | 一种含有多奈哌齐的透皮贴剂及其制备方法 |
KR102227100B1 (ko) * | 2020-08-14 | 2021-03-12 | 주식회사 종근당 | 도네페질 에테르 팔미테이트 또는 이의 약제학적으로 허용가능한 염 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11315016A (ja) | 1998-03-03 | 1999-11-16 | Eisai Co Ltd | 抗痴呆薬を含有した経皮適用製剤又は坐剤 |
US6670417B2 (en) | 2001-03-16 | 2003-12-30 | National Starch And Chemical Investment Holding Corporation | Rubber-acrylic adhesive formulation |
US20040258741A1 (en) | 2001-10-17 | 2004-12-23 | Takaaki Terahara | Percutaneous absorption preparations |
US20080138388A1 (en) | 2005-02-04 | 2008-06-12 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal Absorption Patch |
US20090175929A1 (en) | 2006-05-09 | 2009-07-09 | Takaaki Terahara | Transdermally absorbable Donepezil Preparation |
KR20090101667A (ko) | 2008-03-24 | 2009-09-29 | 아이큐어 주식회사 | 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제 |
US20100080842A1 (en) | 2008-09-30 | 2010-04-01 | Jianye Wen | Transdermal extended-delivery donepezil compositions and methods for using the same |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002069942A1 (fr) * | 2001-03-07 | 2002-09-12 | Hisamitsu Pharmaceutical Co., Inc. | Timbre adhesif |
KR100885931B1 (ko) * | 2002-03-25 | 2009-02-26 | 내쇼날 스타치 앤드 케미칼 인베스트멘트 홀딩 코포레이션 | 고무-아크릴계 접착제 |
BRPI0621655A2 (pt) | 2006-05-08 | 2011-12-20 | Teikoku Seiyaku Kk | preparação para a absorção percutánea de uma droga antidemência básica |
JP2009540052A (ja) * | 2006-06-06 | 2009-11-19 | ダウ・コーニング・コーポレイション | シリコーンアクリレートハイブリッド組成物およびその製造方法 |
US20100048628A1 (en) | 2006-12-01 | 2010-02-25 | Sumiyo Nishi | Method for suppressing discoloration over time of adhesive preparation containing donepezil |
CA2670991A1 (en) * | 2006-12-01 | 2008-06-05 | Nitto Denko Corporation | Percutaneously absorbable preparation comprising donepezil |
US20090098191A1 (en) | 2007-10-16 | 2009-04-16 | Anderson Christopher G | Use of bases to stabilize transdermal formulations |
US20090291127A1 (en) * | 2008-05-21 | 2009-11-26 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
WO2011034323A2 (en) * | 2009-09-16 | 2011-03-24 | Samyang Corporation | Transdermal delivery system, method for manufacturing the same, and transdermal delivery method using the system |
-
2009
- 2009-07-15 NZ NZ60535209A patent/NZ605352A/xx not_active IP Right Cessation
-
2010
- 2010-06-30 KR KR20100062433A patent/KR101192969B1/ko active IP Right Grant
-
2011
- 2011-04-27 EP EP11801047.9A patent/EP2589379B1/en active Active
- 2011-04-27 MY MYPI2012005653A patent/MY163809A/en unknown
- 2011-04-27 ES ES11801047T patent/ES2785992T3/es active Active
- 2011-04-27 AU AU2011272174A patent/AU2011272174A1/en not_active Abandoned
- 2011-04-27 US US13/806,565 patent/US9155711B2/en active Active
- 2011-04-27 JP JP2013518221A patent/JP5680197B2/ja not_active Expired - Fee Related
- 2011-04-27 CN CN201180032581.1A patent/CN103096882B/zh not_active Expired - Fee Related
- 2011-04-27 CA CA2804148A patent/CA2804148C/en not_active Expired - Fee Related
- 2011-04-27 SG SG2012093944A patent/SG186777A1/en unknown
- 2011-04-27 WO PCT/KR2011/003052 patent/WO2012002640A2/ko active Application Filing
-
2015
- 2015-08-12 US US14/825,071 patent/US9693970B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11315016A (ja) | 1998-03-03 | 1999-11-16 | Eisai Co Ltd | 抗痴呆薬を含有した経皮適用製剤又は坐剤 |
US6670417B2 (en) | 2001-03-16 | 2003-12-30 | National Starch And Chemical Investment Holding Corporation | Rubber-acrylic adhesive formulation |
US20040258741A1 (en) | 2001-10-17 | 2004-12-23 | Takaaki Terahara | Percutaneous absorption preparations |
KR20050037405A (ko) | 2001-10-17 | 2005-04-21 | 히사미쯔 제약 주식회사 | 경피 흡수형 제제 |
US20080138388A1 (en) | 2005-02-04 | 2008-06-12 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal Absorption Patch |
US20090175929A1 (en) | 2006-05-09 | 2009-07-09 | Takaaki Terahara | Transdermally absorbable Donepezil Preparation |
KR20090101667A (ko) | 2008-03-24 | 2009-09-29 | 아이큐어 주식회사 | 도네페질을 유효성분으로 함유하는 치매 치료용경피흡수제제 |
US20100080842A1 (en) | 2008-09-30 | 2010-04-01 | Jianye Wen | Transdermal extended-delivery donepezil compositions and methods for using the same |
Non-Patent Citations (1)
Title |
---|
See also references of EP2589379A4 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014502639A (ja) * | 2011-01-12 | 2014-02-03 | タイワン バイオテック カンパニー リミテッド | ドネペジル経皮吸収型パッチ及びアルツハイマー病の治療方法 |
WO2014159778A1 (en) * | 2013-03-13 | 2014-10-02 | Nal Pharmaceuticals, Ltd. | Transdermal drug delivery system containing fentanyl |
WO2014159748A1 (en) * | 2013-03-13 | 2014-10-02 | Nal Pharmaceuticals, Ltd. | Transdermal drug delivery system containing donepezil |
US20140271866A1 (en) * | 2013-03-15 | 2014-09-18 | Nal Pharmaceuticals, Ltd. | Transdermal drug delivery system containing rivastigmine |
JP2016522792A (ja) * | 2013-03-15 | 2016-08-04 | エヌエーエル ファーマスーティカル グループ リミテッド | リバスチグミンを含む、経皮薬物送達システム |
US10195408B2 (en) | 2014-02-20 | 2019-02-05 | Nal Pharmaceutical Group Limited | Transdermal drug delivery system containing donepezil |
Also Published As
Publication number | Publication date |
---|---|
MY163809A (en) | 2017-10-31 |
JP2013529680A (ja) | 2013-07-22 |
CA2804148A1 (en) | 2012-01-05 |
CA2804148C (en) | 2018-03-20 |
JP5680197B2 (ja) | 2015-03-04 |
AU2011272174A1 (en) | 2013-01-24 |
KR101192969B1 (ko) | 2012-10-19 |
ES2785992T3 (es) | 2020-10-08 |
US9693970B2 (en) | 2017-07-04 |
US20130095168A1 (en) | 2013-04-18 |
CN103096882A (zh) | 2013-05-08 |
WO2012002640A3 (ko) | 2012-04-12 |
CN103096882B (zh) | 2014-06-11 |
SG186777A1 (en) | 2013-02-28 |
US20150352058A1 (en) | 2015-12-10 |
EP2589379A4 (en) | 2013-12-18 |
EP2589379A2 (en) | 2013-05-08 |
KR20120001844A (ko) | 2012-01-05 |
EP2589379B1 (en) | 2020-02-26 |
US9155711B2 (en) | 2015-10-13 |
NZ605352A (en) | 2013-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012002640A2 (ko) | 도네페질을 함유하는 경피흡수제제 | |
WO2009120002A2 (ko) | 도네페질을 유효성분으로 함유하는 치매 치료용 경피흡수제제 | |
WO2012124966A2 (ko) | 펜타닐 경피 패치제 | |
JP6391664B2 (ja) | リバスチグミンを含む、経皮薬物送達システム | |
EP0561983B1 (en) | Systems for administering drugs transdermally using sorbitan esters as skin permeation enhancers | |
US20140370076A1 (en) | Transdermal drug delivery system containing donepezil | |
JP5632577B2 (ja) | 貼付剤 | |
WO2012111996A2 (ko) | 갈란타민 또는 그의 염을 함유하는 경피흡수제제 | |
KR20050111317A (ko) | 혈소판혈병의 치료를 위한 제형 및 방법 | |
WO2014159748A1 (en) | Transdermal drug delivery system containing donepezil | |
WO2013028032A1 (ko) | 경피 흡수 제제 및 그 제조방법 | |
WO2018080214A1 (ko) | 수면장애 치료용 경피흡수제제 | |
US20140370077A1 (en) | Transdermal drug delivery system containing fentanyl | |
KR101566817B1 (ko) | 케토티펜 또는 그 염을 함유하는 경피흡수제제 | |
KR100340100B1 (ko) | 진양 첩부제 조성물 및 경피투여시스템 | |
WO2015072683A1 (ko) | 셀레질린 또는 그의 약학적으로 허용가능한 염을 함유하는 경피흡수제제 | |
KR20190048320A (ko) | 바레니클린 경피흡수제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180032581.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11801047 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2748/MUMNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011801047 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013518221 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2804148 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13806565 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011272174 Country of ref document: AU Date of ref document: 20110427 Kind code of ref document: A |